Safety of MT-401-OTS in Patients With Relapsed AML or MDS
NCT06552416
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia, in Relapse
MDS
Interventions
DRUG:
MT-401-OTS
Sponsor
Marker Therapeutics, Inc.
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]